Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Glucocorticoid-induced osteoporosis.

I R Reid1

  • 1Department of Medicine, University of Auckland, Private Bag 92019, Auckland, New Zealand.

Bailliere'S Best Practice & Research. Clinical Endocrinology & Metabolism
|October 19, 2000
PubMed
Summary

Glucocorticoid medications cause bone loss by reducing bone formation. Strategies to mitigate this include reducing steroid dosage, increasing calcium and vitamin D intake, and lifestyle changes. Bisphosphonates are recommended for high-risk patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

What is the risk of cardiovascular events in osteoporotic patients treated with romosozumab?

Expert opinion on drug safety·2022
Same author

Bone-friendly lifestyle and the role of calcium or vitamin D supplementation.

Climacteric : the journal of the International Menopause Society·2021
Same author

Publisher Correction to: Development of the Asia Pacific Consortium on Osteoporosis (APCO) framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Development of the Asia Pacific Consortium on Osteoporosis (APCO) Framework: clinical standards of care for the screening, diagnosis, and management of osteoporosis in the Asia-Pacific region.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2021
Same author

Management of Paget's disease of bone.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2019
Same author

Anti-fracture efficacy of zoledronate in subgroups of osteopenic postmenopausal women: secondary analysis of a randomized controlled trial.

Journal of internal medicine·2019

Area of Science:

  • Endocrinology
  • Bone Metabolism
  • Pharmacology

Background:

  • Glucocorticoid drugs significantly impact bone metabolism.
  • These medications reduce osteoblast activity and bone matrix synthesis.
  • Bone loss occurs in most patients exceeding 5 mg/day of glucocorticoids.

Purpose of the Study:

  • To review the effects of glucocorticoids on bone metabolism.
  • To identify predictors of fracture risk in patients on glucocorticoids.
  • To outline strategies for managing and preventing steroid-induced bone loss.

Main Methods:

  • Review of existing literature on glucocorticoid effects on bone.
  • Analysis of factors influencing bone density and fracture risk.
  • Evaluation of interventions for managing steroid-induced osteoporosis.

Main Results:

  • Bone loss is dose-dependent and cumulative.
  • Initial bone density, patient demographics, and lifestyle factors predict fracture risk.
  • Steroid-induced bone loss is reversible with appropriate management.

Conclusions:

  • Minimizing glucocorticoid dosage or discontinuation is crucial.
  • Lifestyle modifications (calcium, vitamin D, exercise, smoking cessation) are beneficial.
  • Bisphosphonates and sex hormone replacement are effective in high-risk individuals.

Related Experiment Videos